Comparison of Decolonization of Methicillin-Resistant Staphylococcus Aureus (MRSA) Using Theraworx
Information source: St. John's Health System
Information obtained from ClinicalTrials.gov on October 19, 2009
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Methicillin-Resistant Staphylococcus Aureus
Intervention: Theraworx (Other); mupirocin antibiotic ointment (Drug)
Phase: N/A
Status: Recruiting
Sponsored by: St. John's Health System Official(s) and/or principal investigator(s):
Roger E Huckfeldt, MD, Principal Investigator, Affiliation: St. Johns' Health System-Medical Research Institute
Overall contact:
Roger E Huckfeldt, MD, Phone: 417-820-3185, Email: roger.huckfeldt@mercy.net
Summary
The purpose of this study is to examine treatment method of Methicillin-resistant
Staphylococcus aureus (MRSA) decolonization in patients.
Clinical Details
Official title: Comparison of Decolonization of MRSA Using Theraworx
Study design: Treatment, Randomized, Single Blind (Subject), Parallel Assignment, Safety/Efficacy Study
Primary outcome: Evidence of decolonization confirmed by intranasal culture
Secondary outcome: Economic-Cost comparison of treatment
Evidence of decolonization
Detailed description:
Decolonization therapy is indicated for management of patients with MRSA. Theraworx is
reported to be an effective antimicrobial against multiple organisms. In this study,
patients with positive MRSA colonization culture will be treated with Theraworx to evaluate
decolonization duration capability.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Positive MRSA culture
Exclusion Criteria:
- Patients currently on or start antibiotic therapy directed for MRSA.(Prophylaxis
antibiotic for surgical procedure not considered therapy.)
- Patients with MRSA infected wounds
- Patients under the age of 18 years
- A woman currently pregnant or nursing a child
- Patients participating in another study within 30 days of randomization
Locations and Contacts
Roger E Huckfeldt, MD, Phone: 417-820-3185, Email: roger.huckfeldt@mercy.net
St John's Hospital-Medical Research Institute, Springfield, Missouri 65804, United States; Recruiting
Roger E Huckfeldt, MD, Principal Investigator
Additional Information
Starting date: March 2008
Ending date: March 2009
Last updated: July 10, 2008
|
